Sangamo Therapeutics, Inc. (SGMO)
| Market Cap | 1.48B |
| Revenue (ttm) | 131.40M |
| Net Income (ttm) | -124.02M |
| Shares Out | 143.11M |
| EPS (ttm) | -0.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $10.17 |
| Previous Close | $10.54 |
| Change ($) | -0.37 |
| Change (%) | -3.51% |
| Day's Open | 10.39 |
| Day's Range | 10.05 - 10.46 |
| Day's Volume | 1,017,475 |
| 52-Week Range | 8.51 - 19.43 |
Sangamo (SGMO) delivered earnings and revenue surprises of -10.34% and -17.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2021 financial results. “This quarte...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investo...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24th Annual Meeting of the American Society o...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2021 financial r...
Sangamo Therapeutics, a biotechnology company that focuses on multiple areas in the genomic medicine space, including gene therapy, cell therapy, and in vivo genome editing, looks attractive at current ...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in the virtual Guggenheim Healthcare Talks: 202...
Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
Earlier this month, we discussed that the stock price of Sangamo Therapeutics, a biotechnology company that focuses on multiple areas in the genomic medicine space, may trend higher in the near term, ba...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency's Committee for Orphan Medicinal Products (CO...
The stock price of Sangamo Therapeutics, a biotechnology company that focuses on multiple areas in the genomic medicine space, including gene therapy, cell therapy, in vivo genome editing, and in vivo g...
Sangamo (SGMO) delivered earnings and revenue surprises of -61.11% and -31.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial results and recent business highlight...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Cow...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head ...
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on In...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opp...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39th Annual J.P. Morgan...
Sangamo: 'Good Companies Get Bought, Not Sold'
Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.
In the Century of Biology, it pays to own the future of curing disease at the root.
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/...
Gene regulation targeted at RNA or DNA has enormous potential for previously intractable nervous system disorders. Allele-specific gene regulation is a more precise approach targeting only the mutant ge...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences: 29th Annual ...
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call Transcript
Sangamo (SGMO) delivered earnings and revenue surprises of 95.83% and 101.79%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights. “We are plea...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 financial r...
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dose...
Sangamo Therapeutic, Inc. (NASDAQ: SGMO) is a clinical-stage biotech focused on genomic medicines using proprietary platform technologies covering gene therapy, ex-vivo gene-edited cell therapy, and in-...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc.
A Relative Strength Rating upgrade for Sangamo Therapeutics shows improving technical performance. Will it continue?
Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?
A Relative Strength Rating upgrade for Sangamo Therapeutics shows improving technical performance. The post Stocks With Rising Relative Price Strength: Sangamo Therapeutics appeared first on Investor's ...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2020 Results - Earnings Call Transcript
Sangamo (SGMO) delivered earnings and revenue surprises of -163.41% and -71.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc.
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc.
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc.
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Biogen collaboration was completed in 2Q. Cash is now expected to fund operations beyond BLA timing for Hemophilia A.
These three stocks are positioned for growth -- but investors must tread carefully in the short term.
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization. Going forward, research and development will each be ma...
While the data looks good so far, the duo's treatment is behind a similar BioMarin therapy in the testing and approval process.
Investors need to pay close attention to Sangamo (SGMO) stock based on the movements in the options market lately.
Each company aims to use its genome editing platform to treat disease, but which has an edge?
About SGMO
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expressio... [Read more...]
| Industry Biotechnology | IPO Date Apr 6, 2000 |
| CEO Alexander Macrae | Employees 413 |
| Stock Exchange NASDAQ | Ticker Symbol SGMO |
Financial Performance
In 2020, SGMO's revenue was $118.19 million, an increase of 15.39% compared to the previous year's $102.43 million. Losses were -$121.00 million, 27.1% more than in 2019.
Analyst Forecasts
According to 11 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is 19.73, which is an increase of 94.00% from the latest price.